Table 1.
Characteristics of studies that met our inclusion criteria
| Author, Year | Location | Study Type | Antiviral | Patients (N) | Follow-up (months) | HCC (N) | Baseline Age (Years) | Baseline % cirrhosis | HBeAg positive (N) | HBeAg positive (%) †† | Baseline HBV DNA (log10 IU/mL) | Baseline ALT (IU/mL) | Virologic Response (%) | Biochemical Response (%) | HBeAg loss (N) | Incident HCC (%) over time (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Batirel et al 2014 | Turkey | Observational | ETV | 90 | 27.2 | 0 | 43.3 ± 12.9 | 0 | 29 | 32 | 8.28 | 116.7 ± 92.6 | 86 | 98 | 7 | n/a |
| TDF | 105 | 33 | 0 | 42 ± 11.2 | 0 | 36 | 34 | 8.34 | 120 ± 96.6 | 86 | 99 | 16 | n/a | |||
| Wu et al 2017 | Taiwan | Observational | ETV | 313 | 49 | 21 | 47 ± 12.3 | 30 | 172 | 55 | 7.18 (0.74) | 316 | 88 | 82 | 57 | 6.7 (48) |
| TDF | 106 | 37.9 | 8 | 47.1 ± 12.1 | 27 | 50 | 47 | 7.36 (0.7) | 303 | 91 | 84 | 148 | 7.7 (48) | |||
| Riveiro-Barciela et al 2017 | Spain | Observational | ETV | 187 | 55 ± 22 | 3 | 50 ± 13 | 34 | 34 | 18 | 4.9 | 138 ± 367 | 100 | 92 | 11 | n/a |
| TDF | 424 | 49 ± 29 | 11 | 50 ± 13 | 31 | 67 | 16 | 3.8 | 68 ± 139 | 98 | 88 | 16 | n/a | |||
| Choi et al 2018 | South Korea | Observational | ETV | 11464 | 51 (40.4, 55.4) | 590 | 49.3 ± 9.8 | 26 | NA | NA | 6.7 (5.6, 7.9) | 32 (21, 54) | NA | NA | NA | 5.1† (48) |
| TDF | 12692 | 36 (29.3, 42.1) | 394 | 48.6 ± 9.8 | 27 | NA | NA | 6.4 (5.4, 7.6) | 35 (24, 58) | NA | NA | NA | 3 † (48) | |||
| Kim BG et al 2018 | South Korea | Observational | ETV | 721 | 66 | 40 | 52 ± 11 | 48 | 430 | 60 | 6.4 (1.4) | 143.1 ± 172.4 | 98 | NA | NA | 5.1 (48) |
| TDF | 604 | 33 | 14 | 50 ± 11 | 44 | 376 | 63 | 6.0 (1.6) | 136.5 ± 228.1 | 95 | NA | NA | 4.0 (48) | |||
| Yu et al 2018 | South Korea | Observational | ETV | 406 | 69.9 | 31 | 53 ± NA | 36 | 212 | 52 | 6.1 | 93 | 82 | NA | NA | 4.0 (48) |
| TDF | 176 | 33.6 | 7 | 49 ± NA | 44 | 104 | 59 | 6.93 | 100 | 83 | NA | NA | 5.0 (48) | |||
| Kayaaslan et al 2018 | Turkey | Observational | ETV | 166 | 48 | 0 | 43 ± NA | 0 | 56 | 34 | 6.92 | 89 | 97 | 92 | 10 | n/a |
| TDF | 86 | 18 | 0 | 42 ± NA | 0 | 41 | 48 | 6.6 | 92 | 69 | 83 | 5 | n/a | |||
| Kim YM et al 2018 | South Korea | Observational | TDF | 112 | 38.5 ± 9.2 | 3 | 49.3 ± 10.9 | 26.8 | 62 | 55 | 6.0 ± 1.5 | 67 (36–145) | 91.1 | NA | NA | n/a |
| ETV | 191 | 66.6 ± 26.8 | 13 | 47.7 ± 12.3 | 27.8 | 116 | 61 | 6.3 ± 1.2 | 124.5 (71–246) | 94.2 | NA | NA | n/a | |||
| Cai et al 2019 | China | RCT | TDF | 157 | 33.2 | 0 | 30.8 ± 8.7 | 0 | 157 | 100 | 7.57 ± 0.93 | NA | 92 | 86.3 | 51 | n/a |
| ETV | 158 | 33.2 | 0 | 30.9 ± 8.4 | 0 | 158 | 100 | 7.69 ± 0.98 | NA | 87 | 87.7 | 55 | n/a | |||
| Kim SU et al 2019 | South Korea | Observational | TDF | 1413 | 59.2 | 102 | 48.8 ± 12 | 29.1 | 694 | 49 | 5.4 ± 2.1 | NA | 87.5 | NA | NA | 7.7 (60) |
| ETV | 1484 | 59.2 | 138 | 48.2 ± 11.5 | 33.6 | 758 | 51 | 5.7 ± 2.1 | NA | 86.5 | NA | NA | 9.3 (60) | |||
| Yip et al 2019 | Hong Kong | Observational | TDF | 1309 | 33.6 | 8 | 43.2 ± 13.1 | 3 | 723 | 55 | 4.8 | 43 | 72 | 58 | 248 | 1.1 (60) |
| ETV | 28041 | 44.4 | 1386 | 53.4 ± 13.0 | 13 | 8306 | 30 | 5.3 | 62 | 75 | 69 | 287 | 7.0 (60) | |||
| Lee at al 2019 | South Korea | Observational | TDF | 1439 | 36.4 | 50 | 47.29 ± 11.16 | 34 | 823 | 57 | 6.41 (5.34, 7.49) | 94 (51, 194) | 97.7 | 86.7 | NA | 5.6 (60) |
| ETV | 1583 | 60 | 84 | 46.66 ± 11.76 | 36 | 974 | 62 | 6.49 (5.28, 7.67) | 98 (53, 201) | 91.4 | 91.6 | NA | 5.5 (60) | |||
| Gordon et al 2019††† | USA | Observational | TDF | 407 | 48 | 13 | 48 | NA | NA | NA | NA | NA | NA | NA | NA | n/a |
| ETV | 415 | 66 | 18 | 51 | NA | NA | NA | NA | NA | NA | NA | NA | n/a | |||
| Hsu et al 2019 | Multinational | Observational | ETV | 4387 | 60 (39.6–60) | 285 | 50.81 ± 0.17 | 27.8 | 1537 | 35 | 5.48 ± 0.03 | 200 ±5.65 | NA | NA | NA | 7.3 (60) |
| TDF | 700 | 38.7 (23.8–56.2) | 13 | 45.74 ± 0.47 | 18.7 | 208 | 30 | 4.99 ± 0.09 | 147 ± 11.28 | NA | NA | NA | 3.2 (60) |
ETV = Entecavir; TDF = tenofovir disoproxil; HCC = hepatocellular carcinoma; HBeAg = Hepatitis B e Antigen; HBV = hepatitis B virus; ALT = alanine transaminase
n/a = not available or not-applicable
†
= estimated based on time-to-event graph
††
= % less accurate than N, due to lack of universal HBeAg testing
†††
= abstract only